[Treatment of hepatitis C: what is known?].
Treatment of hepatitis C is changing dramatically. Various new direct-acting antivirals (DAA) against HCV have recently been approved or will become available during the next months. To summarize the efficacy of DAAs and to describe optimal treatment regimens for chronic hepatitis C. Review of selected phase 2 and 3 trials investigating anti-HCV drugs and recent HCV guidelines. New HCV therapies are interferon-free and lead to sustained HCV clearance in >90% of cases. DAAs include HCV protease inhibitors, NS5A inhibitors as well as nucleotide and non-nucleoside HCV polymerase inhibitors. Depending on the stage of liver disease, HCV genotype and viral load, treatment duration is 8-24 weeks. Ribavirin is not needed anymore in every case. Resistance against HCV drugs is not a major factor determining treatment response, but resistance testing is recommended in case of treatment failures before re-treatment is considered. Chronic hepatitis C is a curable disease. It remains to be determined to what extent HCV clearance will alter liver function and the risk for hepatocellular carcinoma in patients with liver cirrhosis.